Association between radiotherapy protocol variations and outcome in the CONVERT trial

Brown, 2019, The evolving role of radiotherapy in non-small cell lung cancer, BJR, 92, 20190524, 10.1259/bjr.20190524 Nestle, 2018, ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer, Radiother Oncol, 127, 1, 10.1016/j.radonc.2018.02.023 LePechoux, 2020, ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer, Radiother Oncol, 152, 89, 10.1016/j.radonc.2020.07.012 Miles, 2019, SP-008 ensuring quality in an image guidance era, Radiother Oncol, 133, S4, 10.1016/S0167-8140(19)30428-1 Peters, 2010, Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02, JCO, 28, 2996, 10.1200/JCO.2009.27.4498 Brade, 2018, Radiation Therapy Quality Assurance (RTQA) of concurrent Chemoradiation therapy for locally advanced non-small cell lung cancer in the PROCLAIM phase 3 trial, IJROBP, 101, 927 Gkika, 2021, The impact of radiotherapy protocol adherence on the outcome of patients with locally advanced NSCLC treated with concurrent chemoradiation: results from the radiotherapy quality assurance of the multicentre international randomized PET-Plan trial, Radiother Oncol, 10.1016/j.radonc.2021.07.017 Aird, 1995, Quality assurance in the CHART clinical trial, Radiother Oncol, 36, 235, 10.1016/0167-8140(95)01598-B Martel-Lafay, 2014, Impact of irradiation protocol deviations on the outcome of unresectable stage III NSCLC patients receiving concurrent chemoradiotherapy: Quality-assurance results of the GFPC-IFCT 02.01 trial, Appl Radiol Faivre-Finn, 2016, BMJ Open, 6, e009849, 10.1136/bmjopen-2015-009849 Melidis, 2015, Radiation therapy quality assurance in clinical trials – Global harmonization group, Radiother Oncol, 111, 327, 10.1016/j.radonc.2014.03.023 Groom, 2014, Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer, BJR, 87, 20130653, 10.1259/bjr.20130653 Thor, 2020, Using auto-segmentation to reduce contouring and dose inconsistency in clinical trials: the simulated impact on RTOG 0617, IJROBP, 109, 1619 Wang, 2017, Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy, JCO, 35, 1387, 10.1200/JCO.2016.70.0229 Zhang, 2019, Is the importance of heart dose overstated in the treatment of non-small cell lung cancer? A systematic review of the literature, IJROBP, 104, 582 Bradley, 2015, Lancet Oncol, 16, 187, 10.1016/S1470-2045(14)71207-0 Colinet, 2005, Pujol J-l on behalf of the oncoLR health network. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson’s index, Br J Cancer, 93, 1098, 10.1038/sj.bjc.6602836 Banfill, 2020, Cardiac toxicity of thoracic radiotherapy: exisiting evidence and future directions, JTO, 16, 216 Mir, 2020, Organ at risk delineation for radiation therapy clinical trials: global Harmonization Group consensus guidelines, Radiother Oncol, 150, 30, 10.1016/j.radonc.2020.05.038 Vandewinckele, 2020, Overview of artificial intelligence-based applications in radiotherapy: recommendations for implementation and quality assurance, Radiother Oncol, 153, 55, 10.1016/j.radonc.2020.09.008